Interleukin-1β-Targeted Vaccine Improves Glucose Control and β-Cell Function in a Diabetic KK-Ay Mouse Model
Fig 7
Bioactivity and safety assessment of 1βEPP.
(A) In vivo inflammatory activity. Groups of C57BL/6J mice were received i.p. injection of 1μg hIL-1β, IL-1β epitope peptide or s.c. injection of 50 μg 1βEPP. Three hours later, serum IL-6 levels were quantified using an IL-6 quantitative ELISA kit. (B) Effects of endogenous IL-1β on antibody titer. KK-Ay mice were immunized once with 1βEPP and subsequently i.p. injected with 1 ng lipopolysaccharide and 20 mg N-galactosamine or s.c. injected with 50 μg 1βEPP. Antibody titer was measured before injection and 10 days thereafter. (C) In vivo neutralization activity to IL-1β. After immunized with either 1βEPP or PLA for three times, KK-Ay mice were received i.p. injection of 1 μg hIL-1β, three hours later, serum IL-6 levels were quantified using an IL-6 quantitative ELISA kit. Data are shown as mean ± SEM (n = 6). *p < 0.05, ***p < 0.001.